SCHEMBL256769

SCHEMBL256769

COCc1cc(C(=O)c2ccccc2)n(C)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 2/20 0.38
HDAC10 Q969S8 2/20 0.38
LMNA P02545 2/20 0.38
GLA P06280 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.38
PGR P06401 1/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
SLC6A2 P23975 1/20 0.38
PDE4A P27815 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HRH1 P35367 1/20 0.38
HTT P42858 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PDE4D Q08499 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256766 0.89 TSHR (0.42) ALDH1A1KDM4EMAPTHDAC10LMNA
SCHEMBL10046853 0.76 FNTA (0.44) ALDH1A1MAPTHDAC10LMNAGLA
SCHEMBL257680 0.75 GABRA1 (0.50) ALDH1A1KDM4EMAPTHDAC10LMNA
SCHEMBL15100671 0.72 ALDH1A1 (0.45) ALDH1A1KDM4EMAPTGLASMN1; SMN2
SCHEMBL15100751 0.71 PGR (0.45) ALDH1A1KDM4EMAPTHDAC10GLA
SCHEMBL257671 0.71 GABRA1 (0.46) ALDH1A1HDAC10LMNASMN1; SMN2CYP1A2
SCHEMBL256764 0.70 ALDH1A1 (0.49) ALDH1A1KDM4EMAPTGLASMN1; SMN2
SCHEMBL15100749 0.70 TSHR (0.46) ALDH1A1MAPTHDAC10GLASMN1; SMN2
SCHEMBL11618005 0.70 POLB (0.49) ALDH1A1KDM4ELMNACYP1A2PGR
SCHEMBL11358475 0.70 KDM4E (0.53) ALDH1A1KDM4ELMNACYP1A2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 ALDH1A1 538/4885KDM4E 2413/4885MAPT 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.